184 related articles for article (PubMed ID: 29045658)
1. Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-κB Activation.
Iwaya C; Nomiyama T; Komatsu S; Kawanami T; Tsutsumi Y; Hamaguchi Y; Horikawa T; Yoshinaga Y; Yamashita S; Tanaka T; Terawaki Y; Tanabe M; Nabeshima K; Iwasaki A; Yanase T
Endocrinology; 2017 Dec; 158(12):4218-4232. PubMed ID: 29045658
[TBL] [Abstract][Full Text] [Related]
2. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
3. Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth.
Nomiyama T; Kawanami T; Irie S; Hamaguchi Y; Terawaki Y; Murase K; Tsutsumi Y; Nagaishi R; Tanabe M; Morinaga H; Tanaka T; Mizoguchi M; Nabeshima K; Tanaka M; Yanase T
Diabetes; 2014 Nov; 63(11):3891-905. PubMed ID: 24879833
[TBL] [Abstract][Full Text] [Related]
4. Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression.
Shigeoka T; Nomiyama T; Kawanami T; Hamaguchi Y; Horikawa T; Tanaka T; Irie S; Motonaga R; Hamanoue N; Tanabe M; Nabeshima K; Tanaka M; Yanase T; Kawanami D
J Diabetes Investig; 2020 Sep; 11(5):1137-1149. PubMed ID: 32146725
[TBL] [Abstract][Full Text] [Related]
5. Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo.
Nath N; Chattopadhyay M; Rodes DB; Nazarenko A; Kodela R; Kashfi K
Molecules; 2015 Jul; 20(7):12481-99. PubMed ID: 26184135
[TBL] [Abstract][Full Text] [Related]
6. Exendin-4 does not modify growth or apoptosis of human colon cancer cells.
Wenjing H; Shuang Y; Weisong L; Haipeng X
Endocr Res; 2017 Aug; 42(3):209-218. PubMed ID: 28318339
[TBL] [Abstract][Full Text] [Related]
7. Exendin-4 inhibits glioma cell migration, invasion and epithelial-to-mesenchymal transition through GLP-1R/sirt3 pathway.
Nie ZJ; Zhang YG; Chang YH; Li QY; Zhang YL
Biomed Pharmacother; 2018 Oct; 106():1364-1369. PubMed ID: 30119208
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4/ROS/VEGF pathway.
Liu ZZ; Duan XX; Yuan MC; Yu J; Hu X; Han X; Lan L; Liu BW; Wang Y; Qin JF
Life Sci; 2022 Apr; 294():120370. PubMed ID: 35124000
[TBL] [Abstract][Full Text] [Related]
9. Proinflammatory switch from Gαs to Gαi signaling by Glucagon-like peptide-1 receptor in murine splenic monocyte following burn injury.
Zhang QH; Hao JW; Li GL; Ji XJ; Yao XD; Dong N; Yao YM
Inflamm Res; 2018 Feb; 67(2):157-168. PubMed ID: 29022064
[TBL] [Abstract][Full Text] [Related]
10. Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway.
Zhao H; Wang L; Wei R; Xiu D; Tao M; Ke J; Liu Y; Yang J; Hong T
Diabetes Obes Metab; 2014 Sep; 16(9):850-60. PubMed ID: 24641303
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting receptor for advanced glycation end product (AGE) and oxidative stress involved in the protective effect mediated by glucagon-like peptide-1 receptor on AGE induced neuronal apoptosis.
Chen S; Yin L; Xu Z; An FM; Liu AR; Wang Y; Yao WB; Gao XD
Neurosci Lett; 2016 Jan; 612():193-198. PubMed ID: 26679229
[TBL] [Abstract][Full Text] [Related]
12. Exendin-4 inhibits growth and augments apoptosis of ovarian cancer cells.
He W; Yu S; Wang L; He M; Cao X; Li Y; Xiao H
Mol Cell Endocrinol; 2016 Nov; 436():240-9. PubMed ID: 27496641
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells.
Koehler JA; Kain T; Drucker DJ
Endocrinology; 2011 Sep; 152(9):3362-72. PubMed ID: 21771884
[TBL] [Abstract][Full Text] [Related]
14. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
15. Exenatide exhibits anti-inflammatory properties and modulates endothelial response to tumor necrosis factor α-mediated activation.
Garczorz W; Gallego-Colon E; Kosowska A; Kłych-Ratuszny A; Woźniak M; Marcol W; Niesner KJ; Francuz T
Cardiovasc Ther; 2018 Apr; 36(2):. PubMed ID: 29283509
[TBL] [Abstract][Full Text] [Related]
16. Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells.
Fidan-Yaylalı G; Dodurga Y; Seçme M; Elmas L
Tumour Biol; 2016 Feb; 37(2):2647-53. PubMed ID: 26399993
[TBL] [Abstract][Full Text] [Related]
17. Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study.
Mao D; Cao H; Shi M; Wang CC; Kwong J; Li JJX; Hou Y; Ming X; Lee HM; Tian XY; Wong CK; Chow E; Kong APS; Lui VWY; Chan PKS; Chan JCN
EBioMedicine; 2021 Mar; 65():103242. PubMed ID: 33684886
[TBL] [Abstract][Full Text] [Related]
18. Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.
Tsutsumi Y; Nomiyama T; Kawanami T; Hamaguchi Y; Terawaki Y; Tanaka T; Murase K; Motonaga R; Tanabe M; Yanase T
PLoS One; 2015; 10(10):e0139709. PubMed ID: 26439622
[TBL] [Abstract][Full Text] [Related]
19. Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice.
Gumuslu E; Cine N; Ertan M; Mutlu O; Komsuoglu Celikyurt I; Ulak G
Fundam Clin Pharmacol; 2018 Apr; 32(2):174-180. PubMed ID: 29091313
[TBL] [Abstract][Full Text] [Related]
20. The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis.
Zhou M; Mok MT; Sun H; Chan AW; Huang Y; Cheng AS; Xu G
Oncogene; 2017 Jul; 36(29):4135-4149. PubMed ID: 28319060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
